Abstract:More than 650 reversible and irreversible post-translational modifications (PTMs) of proteins have been listed so far. Canonical PTMs of proteins consist of the covalent addition of functional or chemical groups on target backbone amino-acids or the cleavage of the protein itself, giving rise to modified proteins with specific properties in terms of stability, solubility, cell distribution, activity, or interactions with other biomolecules. PTMs of protein contribute to cell homeostatic processes, enabling basal cell functions, allowing the cell to respond and adapt to variations of its environment, and globally maintaining the constancy of the milieu interieur (the body's inner environment) to sustain human health. Abnormal protein PTMs are, however, associated with several disease states, such as cancers, metabolic disorders, or neurodegenerative diseases. Abnormal PTMs alter the functional properties of the protein or even cause a loss of protein function. One example of dramatic PTMs concerns the cellular prion protein (PrPC), a GPI-anchored signaling molecule at the plasma membrane, whose irreversible post-translational conformational conversion (PTCC) into pathogenic prions (PrPSc) provokes neurodegeneration. PrPC PTCC into PrPSc is an additional type of PTM that affects the tridimensional structure and physiological function of PrPC and generates a protein conformer with neurotoxic properties. PrPC PTCC into PrPSc in neurons is the first step of a deleterious sequence of events at the root of a group of neurodegenerative disorders affecting both humans (Creutzfeldt-Jakob diseases for the most representative diseases) and animals (scrapie in sheep, bovine spongiform encephalopathy in cow, and chronic wasting disease in elk and deer). There are currently no therapies to block PrPC PTCC into PrPSc and stop neurodegeneration in prion diseases. Here, we review known PrPC PTMs that influence PrPC conversion into PrPSc. We summarized how PrPC PTCC into PrPSc impacts the PrPC interactome at the plasma membrane and the downstream intracellular controlled protein effectors, whose abnormal activation or trafficking caused by altered PTMs promotes neurodegeneration. We discussed these effectors as candidate drug targets for prion diseases and possibly other neurodegenerative diseases.

Mechanisms of prion-induced toxicity

Prions Mediated Neurodegenerative Disorders.

Prion Protein Oligomer and Its Neurotoxicity

Prion Protein Misfolding, Strains, and Neurotoxicity: An Update from Studies on Mammalian Prions

Prions and protein-folding diseases

Activation of Innate Immunity and Autophagy in Brain Tissues with Prion Disease and Degradation of Abnormal PrPs in Cells — China’s Studies

Molecular Mechanisms of Neurodegeneration Mediated by Dysfunctional Subcellular Organelles in Transmissible Spongiform Encephalopathies

Interaction Between Misfolded PrP and the Ubiquitin-Proteasome System in Prion-Mediated Neurodegeneration.

Extensive Disturbances of Intracellular Components and Dysfunctions of Biological Pathways in the Brain Tissues During Prion Infection — China’s Studies

Prions activate a p38 MAPK synaptotoxic signaling pathway

The Prion Basis of Progressive Neurodegenerative Disorders

Post-translational modifications in prion diseases

Autophagy and Prion Disease

The biological function of the cellular prion protein: an update

Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases

Conformational Conversion of Prion Protein in Prion Diseases.

Targeting Prion-Like Protein Spreading in Neurodegenerative Diseases

Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases

Prion therapeutics: Lessons from the past

Using Protein Misfolding Cyclic Amplification Generates a Highly Neurotoxic PrP Dimer Causing Neurodegeneration

Therapeutic perspectives for prion diseases in humans and animals